- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Earnings call: Nanobiotix reports progress in solid tumor treatment | 1 | Investing.com | ||
| 25.04. | Nanobiotix reports FY results | 1 | Seeking Alpha | ||
| 24.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.04. | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results | 18 | GlobeNewswire (Europe) | Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen") expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102... ► Artikel lesen | |
| 17.04. | Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 | 1 | GlobeNewswire (USA) | ||
| 17.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.04. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| 10.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.04. | Nanobiotix S.A.: Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation | 63 | GlobeNewswire (Europe) | Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer ("NSCLC") who have previously received definitive radiation therapyConfirmation... ► Artikel lesen | |
| 02.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.03. | Nanobiotix S.A.: Nanobiotix to Present at Upcoming Investor Conferences in March | 3 | GlobeNewswire (USA) | ||
| 06.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.02. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 6 | GlobeNewswire (USA) | ||
| 31.01. | Nanobiotix S.A.: Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference | 2 | GlobeNewswire (USA) | ||
| 29.01. | Nanobiotix S.A.: Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study | 249 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| 29.01. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.01. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 26.12.23 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 26.12.23 | Nanobiotix S.A.: Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets | 1.322 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| 13.12.23 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,142 | +3,65 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
| PALATIN TECHNOLOGIES | 1,922 | -1,03 % | Palatin: FDA Clears IND Application For Bremelanotide Phase 2 Study | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN) announced the FDA has completed 30-day review of the investigational new drug application for the use of bremelanotide, a melanocortin... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,860 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenFR0012816825 Biophytis 02.05.2024 FR001400OLP5 Biophytis 03.05.2024 Tausch 400:1US98585K8624 Yield10 Bioscience Inc.... ► Artikel lesen | |
| AMYRIS | 0,039 | 0,00 % | AMYRIS, INC. - 8-K, Current Report | ||
| HALOZYME THERAPEUTICS | 36,780 | -0,86 % | Halozyme Therapeutics, Inc.: Halozyme Reports Fourth Quarter And Full Year 2023 Financial And Operating Results | Reiterating 2024 Financial Guidance: Total Revenue of $915 -985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535 -585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted... ► Artikel lesen | |
| GLOW LIFETECH | 0,023 | 0,00 % | Glow LifeTech Corp.: Glow Announces Closing of Non-Brokered Private Placement | Toronto, Ontario--(Newsfile Corp. - April 26, 2024) - Glow LifeTech Corp. (CSE: GLOW) (OTC Pink: GLWLF) ("Glow" or the "Company") is pleased to announce, that further to its press release of April... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,757 | +0,21 % | AbCellera partners with PE firms to develop antibody drugs, company creation | ||
| BIO-RAD LABORATORIES | 254,90 | -2,00 % | OncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay | - Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option... ► Artikel lesen | |
| AVID BIOSERVICES | 7,150 | -6,54 % | Earnings call: Avid Bioservices sees revenue boost, optimistic on growth | ||
| BIOLINERX | 0,600 | -5,51 % | BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting | TEL AVIV, Israel, April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases... ► Artikel lesen | |
| AADI BIOSCIENCE | 1,830 | -7,11 % | Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) | Subgroup experienced efficacy and safety consistent with overall study population
Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,100 | -1,87 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates | BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,840 | +0,71 % | Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review | RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders... ► Artikel lesen | |
| GEOVAX LABS | 1,743 | 0,00 % | GeoVax, Inc.: GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine | Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing... ► Artikel lesen | |
| COCRYSTAL | 1,540 | +0,65 % | Cocrystal Pharma, Inc. - 8-K, Current Report |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
